Tumor necrosis factor α and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis

Arthritis and Rheumatism

Volumn 60, Issue 9, 2009, Pages 2644-2654

  Schett, Georg ^a   Stolina, Marina ^b   Dwyer, Denise ^b   Zack, Debra ^b   Uderhardt, Stefan ^a   Kr̈onke, Gerhard ^a   Kostenuik, Paul ^b   Feige, Ulrich ^b,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b AMGEN INC   (United States)

^c EUROCBI GmbH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; COLLAGEN; IMMUNOGLOBULIN FC FRAGMENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEGSUNERCEPT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE EROSION; BONE GROWTH; CELL PROLIFERATION; COLLAGEN INDUCED ARTHRITIS; CONTROLLED STUDY; EXPERIMENT; FEMALE; INFLAMMATION; JOINT; KINETICS; MALE; MESENCHYME CELL; NONHUMAN; OSTEOCLAST; OSTEOPHYTE; PERIOSTEUM; PRIORITY JOURNAL; RAT; SYNOVITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL PROLIFERATION; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; MALE; OSTEOCLASTS; OSTEOGENESIS; OSTEOPHYTE; OSTEOPROTEGERIN; POLYETHYLENE GLYCOLS; RANK LIGAND; RATS; RATS, INBRED LEW; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69449086400     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24767     Document Type: Article

References (49)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361
2. McInnes I, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Immunol 2007;7:429-442
3. Goldring SR, Goldring MB. Eating bone or adding it: the Wnt pathway decides. Nat Med 2007;13:133-134 (Pubitemid 46245758)
4. Schett G, Landewe R, van der Heijde D. TNF blockers and structural remodeling in ankylosing spondylitis - what is reality and what is fiction? Ann Rheum Dis 2007;66:709-711
5. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-1488 (Pubitemid 32038586)
6. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309 (Pubitemid 129516268)
7. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002;110:1419-1427 (Pubitemid 35396913)
8. Tat SK, Pelletier JP, Lajeunesse D, Fahmi H, Duval N, Martel-Pelletier J. Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors. Bone 2008;43:284-291
9. Crotti T, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, et al. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002;61:1047-1054 (Pubitemid 35397349)
10. Kearns AE, Khosla S, Kostenuik PJ. OPG and RANKL regulation of bone remodeling in health and disease. Endocr Rev 2008;29:155-192
11. Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, et al. Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 2003;163:2021-2031 (Pubitemid 37310032)
12. Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 2003;42:123-134 (Pubitemid 36131578)
13. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-951 (Pubitemid 28173356)
14. Sakai T, Kambe F, Mitsuyama H, Ishiguro N, Kurokouchi K, Takigawa M, et al. Tumor necrosis factor α induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-κB: abrogation of the tumor necrosis factor α effect by proteosome inhibitors. J Bone Miner Res 2001;16:1272-1280 (Pubitemid 32574656)
15. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:202-213 (Pubitemid 29507155)
16. Cope AP, Aderka D, DohertyM, Engelmann H, Gibbons D, Jones AC, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-1169
17. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-488
18. Ball J. The enthesopathy of ankylosing spondylitis. Br J Rheumatol 1983;22(4 Suppl 2):25-28
19. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes [review]. Arthritis Rheum 2008;58:649-656
20. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-1579 (Pubitemid 40814665)
21. Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum 2003;48:3442-3451 (Pubitemid 37531910)
22. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-163 (Pubitemid 46245765)
23. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 1996;35:373-376 (Pubitemid 26136689)
24. Creemers MC, Franssen MJ, van 't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-129
25. Van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-1331 (Pubitemid 351705922)
26. Lories RJ, Derese I, De Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56:489-497 (Pubitemid 46271975)
27. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000;57:1457-1470 (Pubitemid 30777892)
28. Bolon B, Morony S, Cheng Y, Hu YL, Feige U. Osteoclast numbers in Lewis rats with adjuvant-induced arthritis: identification of preferred sites and parameters for rapid quantitative analysis. Vet Pathol 2004;41:30-36 (Pubitemid 38146844)
29. Frischholz S, Beier F, Girkontaite I, Wagner K, Poschl E, Turnay J, et al. Characterization of human type X procollagen and its NC-1 domain expressed as recombinant proteins in HEK293 cells. J Biol Chem 1998;273:4547-4555 (Pubitemid 28103196)
30. Campagnuolo G, Bolon B, Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002;46:1926-1936 (Pubitemid 34774526)
31. Schett G, Stolina M, Bolon B, Middleton S, Adlam M, Brown H, et al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum 2005;52:3192-3201 (Pubitemid 41447102)
32. Schett G, Middleton S, Bolon B, Stolina M, Brown H, Zhu L, et al. Additive bone-protective effects of anabolic treatment when used in conjuction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 2005;52:1604-1611 (Pubitemid 40663953)
33. Benjamin M, McGonagle D. The anatomical basis for disease localization in seronegative spondylarthropathy at entheses and related sites. J Anat 2001;199:503-526 (Pubitemid 33094612)
34. Iwata K, Li J, Follet H, Phipps RJ, Burr DB. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 2006;39:1053-1058 (Pubitemid 44528380)
35. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res 1999;14:1805-1815 (Pubitemid 29521774)
36. Kitaori T, Ito H, Schwarz EM, Tsutsumi R, Yoshitomi H, Oishi S, et al. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum 2009;60:813-823
37. Olson EJ, Lindgren BR, Carlson CS. Effects of long-term estrogen replacement therapy on bone turnover in periarticular tibial osteophytes in surgically postmenopausal cynomolgus monkeys. Bone 2008;42:907-913
38. Flick LM, Weaver JM, Ulrich-Vinther M, Abuzzahab F, Zhang X, Dougall WC, et al. Effects of receptor activator of NFκB (RANK) signaling blockade on fracture healing. J Orthop Res 2003;21:676-684 (Pubitemid 36758211)
39. Amanat N, McDonald M, Godfrey C, Bilston L, Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 2007;22:867-876 (Pubitemid 351339747)
40. Ulrich-Vinther M, Andreassen TT. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. Calcif Tissue Int 2005;76:280-286 (Pubitemid 40991399)
41. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-4031 (Pubitemid 21905432)
42. Lories RJ, Matthys P, de Vlam K, Derese I, Luyten FP. Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis. Ann Rheum Dis 2004;63:595-598 (Pubitemid 38530208)
43. De Vries BJ, van den Berg WB. Impact of NSAIDS on murine antigen induced arthritis. II. A light microscopic investigation of antiinflammatory and bone protective effects. J Rheumatol 1990;17:295-303.
44. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factor. Nature 1986;319:516-518 (Pubitemid 16212936)
45. Canalis E. Effects of tumor necrosis factor on bone formation in vitro. Endocrinology 1987;121:1596-1604 (Pubitemid 18012760)
46. Lories RJ, Derese I, Luyten FP. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis. Rheumatology (Oxford) 2008;47:605-608 (Pubitemid 351619197)
47. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, et al, for the Health, Aging and Body Composition Study. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004;50:3516-3525
48. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al, for the AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-831
49. Muraki S, Yamamoto S, Ishibashi H, Horiuchi T, Hosoi T, Orimo H, et al. Impact of degenerative spinal diseases on bone mineral density of the lumbar spine in elderly women. Osteoporos Int 2004;15:724-728 (Pubitemid 39222655)